AmitkumarNitinkumaMehtaMD
Oncology • Birmingham, ALHematologic Oncology
Lymphoma Program, Assistant Professor, Hematology & Oncology University of Alabama at Birmingham
Overview of Dr. Mehta
I am currently assistant professor and associate scientist at the University of Alabama at Birmingham Comprehensive Cancer Center (UABCCC). I am board certified in Internal Medicine, Hematology and Oncology. My focus of interest is LYMPHOMA (Hodgkin lymphoma, Non Hodgkin lymphoma-T cell and B cell lymphomas). I specialize in treatments all types of lymphoma in my clinic. I am also involved in lymphoma related research which includes genomic and proteomic (gene and protein related) studies in various kinds of lymphomas. As a clinical investigator I am also part of many clinical trials as principal investigator or sub investigator. Many new promising targeted and immunologic treatment for lymphomas are being developed at UABCCC which patients of lymphoma can benefit. My passion is to develop targeted and immunologic therapies in lymphomas with less toxicities and more effectiveness.
UABCCC lymphoma program is comprehensive program involving all specialists (medical oncology, surgical oncology, radiation oncology, survivorship and integrative medicine) and great nurses.
Apart from lymphomas, I also see patients with blood cancers (Leukemia, Myelodysplastic syndrome, low blood counts, CLL, Langerhans cell histiocytosis, Rosai Dorfman's syndrome etc) and blood related disorders (benign hematology like PTGC, ITP, hemolytic anemia, iron deficiency anemia).
http://www.uab.edu/medicine/hemonc/faculty/amitkumar-mehta-md
Office
2000 6th Ave S
Birmingham, AL 35233- Is this information wrong?
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Providence HospitalResidency, Internal Medicine, 2008 - 2011
Baroda Medical CollegeClass of 2002
Certifications & Licensure
AL State Medical License 2011 - 2024
Awards, Honors, & Recognition
- Chief Resident Providence Hospital, 2011
Clinical Trials
- A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Oct 15
- Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas Start of enrollment: 2014 Dec 01
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Start of enrollment: 2015 May 01
- Join now to see all
Publications & Presentations
PubMed
- Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.Gerson, J., Handorf, E., Villa, D., Gerrie, A., Chapani, P., Li, S., Medeiros, L., Wang, M., Cohen, J., Churnetski, M., Hill, B., Sawalha, Y., Hernandez-Ilizaliturri, ...> ;Blood Advances. 2023 Dec 26
- Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North Am...Barr, P. M., Barr, P. M., Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link, Me...> ;Journal of Hematology & Oncology. 2023 Dec 16
- 3 citationsMosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, Philippe Armand, Tae Min Kim, Dok Hyun Yoon, Amitkumar Mehta, Richard Greil, Jason Westin, Izidore S Lossos, Javie...> ;Blood Advances. 2023 Oct 24
- Join now to see all
Abstracts/Posters
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...Amitkumar Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Adult Clinical Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Other
- Patient-Centered Care in Chronic Lymphocytic LeukemiaUma M. Borate, MD, MS; Amitkumar Mehta, MD; Thomas W. Butler, MD; Richard Taylor, DNP, CRNP; Myeisha D. Hutchinson; Ellen Frederick, RN, BSN, OCN, Medscape Oncology education
http://www.medscape.org/viewarticle/842755
6/15/2015
Press Mentions
UAB Helps College Cheerleader Tackle CancerNovember 16th, 2022
Expensive Gilead, Novartis Cancer Therapies Losing Patients to Experimental TreatmentsJuly 30th, 2019
Blockchain Firm Witty Health Launches Digital Cancer Decision ToolNovember 29th, 2018- Join now to see all
Grant Support
- Young Investigator Award-2014Conquer Cancer Foundation-American Society of Clinical OncologyPresent
Professional Memberships
- Member
- Member
- Member
- American Association of Cancer Research (AACR)Member
Other Languages
- Hindi, Gujarati
Hospital Affiliations
University of Alabama HospitalBirmingham, Alabama
External Links
- UAB Medicinehttp://www.uab.edu/medicine/hemonc/faculty/amitkumar-mehta-md
- LinkedInhttps://www.linkedin.com/pub/amitkumar-mehta/52/98b/199
- Podcast-Oncotherapyhttp://www.oncotherapynetwork.com/podcasts/daratumumab-may-exert-indirect-effects-multiple-myeloma
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
